AUROPHARMA - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:02 am

IntraDay Trade Rating: 4.2

📊 Analysis: AUROPHARMA is trading at ₹1,225, comfortably above both 50 DMA (₹1,171) and 200 DMA (₹1,155), showing strong support levels. RSI at 56.3 indicates moderate bullish momentum, while MACD (4.24) confirms positive trend strength. Current volume (11,90,235) is significantly higher than average weekly volume (6,67,656), suggesting strong intraday participation. Fundamentals are steady with consistent PAT growth, though valuation is slightly premium compared to industry PE.

💡 Optimal Buy Price: Around ₹1,215–₹1,225 (near current support zone).

🎯 Profit-Taking Exit Levels: ₹1,245 (first resistance), ₹1,265 (next resistance).

🛡️ Stop-Loss / Loss Protection: ₹1,205 (below intraday support).

⏱️ If Already Holding: Consider partial exit near ₹1,245 if momentum slows. Full exit if price falls below ₹1,205 with weakening RSI or volume divergence. Strong intraday volume favors holding until resistance levels are tested.

✅ Positive

• 📈 Trading above both 50 DMA and 200 DMA, showing strong technical support.
• 💹 RSI at 56.3 indicates healthy bullish momentum.
• 📊 Volume significantly higher than average, supporting intraday moves.
• 💰 Consistent PAT growth (581 Cr. vs 559 Cr. QoQ).

⚠️ Limitation

• 📉 High PEG ratio (8.25) indicates expensive valuation relative to growth.
• 📊 P/E of 35.2 is above industry PE (30.6).
• 📉 ROCE (10.8%) and ROE (8.65%) are modest compared to valuation.

🚨 Company Negative News

• 📉 Decline in FII holding (-0.17%).

🌟 Company Positive News

• 📈 Increase in DII holding (+0.67%).
• 📊 Strong 52-week performance (+62.3%).

🏭 Industry

• 📊 Industry PE at 30.6, slightly lower than AUROPHARMA’s 35.2, showing premium valuation.
• 💊 Pharma sector demand remains resilient with steady earnings outlook.

📌 Conclusion

AUROPHARMA is a favorable candidate for intraday trading today, supported by strong volume, positive momentum, and technical strength above key moving averages. Optimal entry is near ₹1,215–₹1,225 with profit exits at ₹1,245–₹1,265 and stop-loss at ₹1,205. Momentum indicators suggest cautious optimism for intraday gains.

Would you like me to extend this into a peer benchmarking overlay with other pharma stocks (like Sun Pharma, Cipla, Dr. Reddy’s) to see relative intraday strength, or keep it focused only on AUROPHARMA’s setup?